{"entity":{"id":"nct05093231","kind":"trial","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of pembrolizumab and olaparib in pancreatic cancer, run by Cambridge University Hospitals NHS Foundation Trust, now recruiting.","summary":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT05093231 by Cambridge University Hospitals NHS Foundation Trust, with a registry enrolment figure of 20 participants, started 2025-02-26 and due to reach its primary completion in 2027-07-31. Interventions recorded: Pembrolizumab; Olaparib. Conditions listed: Pancreatic Cancer. Primary outcome: Objective Response Rate (ORR). Sites: Australia, United Kingdom. United Kingdom sites listed: 15. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05093231","url":"https://clinicaltrials.gov/study/NCT05093231"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac","msi-high-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","parp-inhibitor"],"targets":[],"drugs":["pembrolizumab","olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Addenbrooke's Hospital (Cambridge); Glan Clwyd Hospital (Bodelwyddan); Velindre Cancer Centre (Cardiff); University Hospitals Coventry and Warwickshire (Coventry); Beatson West of Scotland Cancer Centre (Glasgow); St James' University Hospital (Leeds); Clatterbridge Cancer Centre (Liverpool); Guy's and St Thomas' NHS Foundation Trust (London); Royal Free Hospital (London); University College London Hospitals NHS Foundation Trust (London); The Christie (Manchester); Milton Keynes University Hospital (Milton Keynes) and 3 more."],"nct":"NCT05093231","phase":"2","setting":"A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb","sponsor":"Cambridge University Hospitals NHS Foundation Trust","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05093231/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}